Results 141 to 150 of about 3,587 (183)

Somatostatin and Its Analogues as Second-Line Treatments in Non-Neoplastic Conditions. [PDF]

open access: yesInt J Mol Sci
Periferakis A   +10 more
europepmc   +1 more source

Terlipressin-Associated Complete Heart Block. [PDF]

open access: yesACG Case Rep J
Song J, Alfie T, Heist EK, Chung RT.
europepmc   +1 more source

Terlipressin: Current and emerging indications in chronic liver disease [PDF]

open access: yesJournal of Gastroenterology and Hepatology (Australia), 2018
Terlipressin is an analogue of vasopressin that has potent vasoactive properties and has been available for use in most countries for nearly two decades.
Timothy Papaluca, Paul Gow
exaly   +2 more sources

Effects of somatostatin, terlipressin and somatostatin plus terlipressin on portal and systemic hemodynamics and renal sodium excretion in patients with cirrhosis

open access: yesJournal of Gastroenterology and Hepatology (Australia), 2005
BACKGROUND AND AIM: Terlipressin and somatostatin are the most preferable agents for the control of variceal bleeding in cirrhotic patients. The present study evaluated the hemodynamic effects of somatostatin, terlipressin and somatostatin plus ...
Georgios Kalambokis   +1 more
exaly   +1 more source

Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome

open access: yesAdvances in Therapy, 2008
Terlipressin is an analog of the natural hormone arginine-vasopressin. It is used in the treatment of patients with cirrhosis and bleeding esophageal varices (BEV) and in patients with hepatorenal syndrome (HRS): two of the most dramatic and feared ...
Aleksander Krag   +2 more
exaly   +2 more sources

Effect of terlipressin on blood volume distribution in patients with cirrhosis

open access: yesScandinavian Journal of Gastroenterology, 2004
Udgivelsesdato: 2004-MayBACKGROUND: Patients with cirrhosis and portal hypertension have an altered blood volume distribution and a hyperdynamic systemic circulation.
Jens H Henriksen   +2 more
exaly   +1 more source

Home - About - Disclaimer - Privacy